Skip to content

Pancreatic Antibiotic Concentration Evaluation Assessment

Pancreatic Antibiotic Concentration Evaluation Assessment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07084428
Acronym
PANACEA
Enrollment
40
Registered
2025-07-24
Start date
2024-01-15
Completion date
2026-06-30
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatic Fluid Collection, Acute Pancreatitis

Keywords

acute pancreatis

Brief summary

This observational study aims to evaluate the penetration of intravenously administered antibiotics into pancreatic fluid collections in patients with suspected infected walled-off pancreatic necrosis (WOPN). In selected patients undergoing percutaneous or endoscopic drainage of the collection as part of their clinical care, a small sample of pancreatic fluid will be collected and analyzed to determine the concentration of the administered antibiotic. At the same time, a blood sample will be taken to assess the antibiotic concentration in plasma. By comparing the concentrations in pancreatic fluid and plasma, the study seeks to determine the extent to which different antibiotics (e.g., meropenem or piperacillin-tazobactam) reach the site of infection within the pancreas. All procedures performed as part of the study, with the exception of the antibiotic concentration measurement, are standard components of routine care for patients with complicated acute pancreatitis. Participation in the study does not alter the diagnostic or therapeutic management of the patient. Patients provide written informed consent before enrollment. The results of this study may help optimize antibiotic dosing in patients with infected pancreatic collections and contribute to more effective and individualized treatment strategies in the future.

Interventions

None listed

Sponsors

Brno University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Signed informed consent * Undergoing percutaneous or endoscopic drainage/puncture of a pancreatic fluid collection

Exclusion criteria

\- Failure or refusal to sign informed consent

Design outcomes

Primary

MeasureTime frameDescription
Antibiotic concentration ratio between pancreatic fluid and plasmaWithin 6 hours after antibiotic administrationRatio of antibiotic concentration in pancreatic fluid (WOPN) to plasma concentration, determined from simultaneously collected samples after intravenous antibiotic administration

Secondary

MeasureTime frameDescription
Measured concentrations of antibiotics in pancreatic fluid and plasmaWithin 6 hours after antibiotic administrationAbsolute concentrations of meropenem and piperacillin in pancreatic fluid and plasma from simultaneously collected samples.

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026